Johnson & Johnson Vision to Acquire TearScience

August 4, 2017: By Jon Swedien

JJV logo x300Johnson & Johnson Vision announced Aug. 4 that it has signed a definitive agreement to acquire TearScience, a Morrisville, North Carolina, company that develops and markets products for meibomian gland dysfunction (MGD), an underlying cause of dry eye disease.

Financial terms were not disclosed.

The deal is expected to close by the end of the year, J&J Vision said. Following the closing, sales will be reported in J&J’s Medical Devices segment, under Vision Care, the company said. J&J Vision’s ophthalmic surgery division is located in Santa Ana, California.

TearScience received FDA clearance in July 2011 for its LipiFlow system, an office-based approach to image meibomian glands and treat MGD. The company sells its products in the US and major markets globally, J&J Vision said.

The TearScience acquisition strengthens J&J Vision’s portfolio, allowing it to provide a critical solution to its optometric and ophthalmic customers who serve dry eye patients, company officials said.

 

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Bausch + Lomb Launches Stellaris Elite for Retinal Surgery in US

Sentencing Delayed for Florida Retina Specialist Melgen

Valeant Receives FDA Complete Response Letter for Vyzulta

US FDA Clears Optovue Software for Corneal Epithelial Thickness Mapping

Ocular Therapeutix Names Daniel Bollag as Regulatory Chief

Eylea Sales Continue to Increase; Lucentis Gains New Indications

RXi Pharmaceuticals Signs Common Stock Purchase Agreement for Up to $15 Million

Allegro’s Luminate Posts Positive Results in Phase IIb Stage 2 Trial for Diabetic Macular Edema

Omeros’ Omidria Revenues Grow 71 Percent

AGTC Receives US FDA Orphan Drug Designation for Gene Therapy to Treat X-Linked Retinitis Pigmentosa

Aerpio Shares Begin Trading on OTCQB Market

Aerie Reports FDA Concerns over Contract Manufacturer’s Plant

Valeant’s Bausch + Lomb Revenues Dip 3 percent in Q2-2017

Ocular Therapeutix Reports $66 Million in Cash, Cash Equivalents

Imprimis’ Q2-2017 Ophthalmology Revenues Increase 70 percent

Carl Zeiss Meditec’s Revenues Grow 7.5 Percent in Latest Quarter

Johnson & Johnson Vision to Acquire TearScience

Mynosys Receives $1 Million Grant from NEI to Commercialize Zepto

Ocular Therapeutix Eliminates 26 Positions; New CEO Takes Helm

Inotek Stops Development of Trabodenoson after Second Failed Study

Coming soon

2017 Glaucoma Pharmaceuticals Report: A Global Market Analysis for 2016 to 2022